Abstract
Lipid-based and polymeric nanotechnologies are poised to dramatically alter the landscape of treatment options for cancer and may hold unique potential for easily accessible, oral chemotherapy. A growing consensus points to nanoscale drug delivery systems as a promising therapeutic modality with enhanced efficacy and diminished side effects and with increasing evidence that these platforms can be engineered to facilitate transport of poorly bioavailable drug compounds and target neoplastic tissue with precision. Significant design and process challenges remain however. The emergence of oral chemotherapeutics in cancer treatment and the role lipid and polymer nanotechnologies play in its development are discussed in this chapter. Several recent research results provide rules of thumb for design and optimization of nanoparticles (i.e., physicochemical and surface properties) to achieve the goals of enhancing intestinal permeability, decreasing immunogenicity and extending circulation half-life, tumor targeting, and minimizing aggregation. Finally, characterization methods to assess drug release and pharmacokinetics will be examined, including dialysis systems, in vitro intestinal co-culture models, microfluidic artificial organs, and in vivo preclinical models.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Findlay, M., von Minckwitz, G., Wardley, A.: Effective oral chemotherapy for breast cancer: pillars of strength. Ann. Oncol. 19(2), 212–222 (2008). https://doi.org/10.1093/annonc/mdm285
Aisner, J.: Overview of the changing paradigm in cancer treatment: Oral chemotherapy. Am. J. Health Syst. Pharm. 64, S4–S7 (2007). https://doi.org/10.2146/ajhp070035
Lu, Y., Park, K.: Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int. J. Pharm. 453(1), 198–214 (2013). https://doi.org/10.1016/j.ijpharm.2012.08.042
Kinch, M.S.: An overview of FDA-approved biologics medicines. Drug Discov. Today. 20(4), 393–398 (2015). https://doi.org/10.1016/j.drudis.2014.09.003
Truong-Le, V., Lovalenti, P.M., Abdul-Fattah, A.M.: Stabilization challenges and formulation strategies associated with oral biologic drug delivery systems. Adv. Drug Deliv. Rev. 93, 95–108 (2015). https://doi.org/10.1016/j.addr.2015.08.001
Thanki, K., Gangwal, R.P., Sangamwar, A.T., Jain, S.: Oral delivery of anticancer drugs: Challenges and opportunities. J. Control. Release. 170(1), 15–40 (2013). https://doi.org/10.1016/j.jconrel.2013.04.020
Wu, P., Nielsen, T.E., Clausen, M.H.: Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discov. Today. 21(1), 5–10 (2016). https://doi.org/10.1016/j.drudis.2015.07.008
Yun, Y., Cho, Y.W., Park, K.: Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv. Drug Deliv. Rev. 65(6), 822–832 (2013). https://doi.org/10.1016/j.addr.2012.10.007
Cone, R.A.: Barrier properties of mucus. Adv. Drug Deliv. Rev. 61(2), 75–85 (2009). https://doi.org/10.1016/j.addr.2008.09.008
Bansil, R., Turner, B.S.: Mucin structure, aggregation, physiological functions and biomedical applications. Curr. Opin. Colloid Interface Sci. 11(2–3), 164–170 (2006). https://doi.org/10.1016/j.cocis.2005.11.001
Malingre, M.M., Richel, D.J., Beijnen, J.H., Rosing, H., Koopman, F.J., Huinink, W.W.T.B., Schot, M.E., Schellens, J.H.M.: Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J. Clin. Oncol. 19(4), 1160–1166 (2001)
Varma, M.V., Obach, R.S., Rotter, C., Miller, H.R., Chang, G., Steyn, S.J., El-Kattan, A., Troutman, M.D.: Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J. Med. Chem. 53(3), 1098–1108 (2010). https://doi.org/10.1021/jm901371v
Jain, A.K., Swarnakar, N.K., Godugu, C., Singh, R.P., Jain, S.: The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials. 32(2), 503–515 (2011). https://doi.org/10.1016/j.biomaterials.2010.09.037
Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., McKendrick, J., Osterwalder, B., Perez-Manga, G., Rosso, R., Rougier, P., Schmiegel, W.H., Seitz, J.F., Thompson, P., Vieitez, J.M., Weitzel, C., Harper, P., Grp, X.C.C.S.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J. Clin. Oncol. 19(21), 4097–4106 (2001)
Herbrink, M., Nuijen, B., Schellens, J.H.M., Beijnen, J.H.: Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat. Rev. 41(5), 412–422 (2015). https://doi.org/10.1016/j.ctrv.2015.03.005
Hu, X.Y., Huang, F., Szymusiak, M., Liu, Y., Wang, Z.J.: Curcumin attenuates opioid tolerance and dependence by inhibiting Ca2+/Calmodulin-Dependent Protein Kinase II alpha activity. J. Pharmacol. Exp. Ther. 352(3), 420–428 (2015). https://doi.org/10.1124/jpet.114.219303
Hu, X.Y., Huang, F., Szymusiak, M., Tian, X.B., Liu, Y., Wang, Z.J.: PLGA-Curcumin Attenuates Opioid-Induced Hyperalgesia and Inhibits Spinal CaMKII alpha. Plos One. 11(1), e0146393 (2016). https://doi.org/10.1371/journal.pone.0146393
Shen, H., Hu, X.Y., Szymusiak, M., Wang, Z.J., Liu, Y.: Orally administered nanocurcumin to attenuate morphine tolerance: comparison between negatively charged PLGA and partially and fully PEGylated nanoparticles. Mol. Pharm. 10(12), 4546–4551 (2013). https://doi.org/10.1021/mp400358z
Szymusiak, M., Hu, X.Y., Plata, P.A.L., Ciupinski, P., Wang, Z.J., Liu, Y.: Bioavailability of curcumin and curcumin glucuronide in the central nervous system of mice after oral delivery of nano-curcumin. Int. J. Pharm. 511(1), 415–423 (2016). https://doi.org/10.1016/j.ijpharm.2016.07.027
Banerjee, A.A., Shen, H., Hautman, M., Anwer, J., Hong, S., Kapetanovic, I.M., Liu, Y., Lyubimov, A.V.: Enhanced oral bioavailability of the hydrophobic chemopreventive agent (Sr13668) in Beagle Dogs. Curr. Pharm. Biotechnol. 14(4), 464–469 (2013)
Shen, H., Banerjee, A.A., Mlynarska, P., Hautman, M., Hong, S., Kapetanovic, I.M., Lyubimov, A.V., Liu, Y.: Enhanced oral bioavailability of a cancer preventive agent (SR13668) by employing polymeric nanoparticles with high drug loading. J. Pharm. Sci. 101(10), 3877–3885 (2012). https://doi.org/10.1002/jps.23269
Pridgen, E.M., Alexis, F., Kuo, T.T., Levy-Nissenbaum, E., Karnik, R., Blumberg, R.S., Langer, R., Farokhzad, O.C.: Transepithelial transport of Fc-Targeted nanoparticles by the Neonatal Fc receptor for oral delivery. Sci. Transl. Med. 5(213), 213ra167 (2013). https://doi.org/10.1126/scitranslmed.3007049
Williams, A.C., Barry, B.W.: Penetration enhancers. Adv. Drug Deliv. Rev. 64, 128–137 (2012). https://doi.org/10.1016/j.addr.2012.09.032
Davis, M.E., Chen, Z., Shin, D.M.: Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771–782 (2008). https://doi.org/10.1038/nrd2614
Torchilin, V.: Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 63(3), 131–135 (2011). https://doi.org/10.1016/j.addr.2010.03.011
Mamidi, R.N.V.S., Weng, S., Stellar, S., Wang, C., Yu, N., Huang, T., Tonelli, A.P., Kelley, M.F., Angiuoli, A., Fung, M.C.: Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products? Cancer Chemother. Pharmacol. 66(6), 1173–1184 (2010). https://doi.org/10.1007/s00280-010-1406-x
Shen, H., Hong, S.Y., Prud'homme, R.K., Liu, Y.: Self-assembling process of flash nanoprecipitation in a multi-inlet vortex mixer to produce drug-loaded polymeric nanoparticles. J. Nanopart. Res. 13(9), 4109–4120 (2011). https://doi.org/10.1007/s11051-011-0354-7
Sun, T.M., Zhang, Y.S., Pang, B., Hyun, D.C., Yang, M.X., Xia, Y.N.: Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed. Engl. 53(46), 12320–12364 (2014). https://doi.org/10.1002/anie.201403036
Parveen, S., Misra, R., Sahoo, S.K.: Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 8(2), 147–166 (2012). https://doi.org/10.1016/j.nano.2011.05.016
Ponchel, G., Montisci, M.J., Dembri, A., Durrer, C., Duchene, D.: Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract. Eur. J. Pharm. Biopharm. 44(1), 25–31 (1997). https://doi.org/10.1016/S0939-6411(97)00098-2
Tang, B.C., Dawson, M., Lai, S.K., Wang, Y.Y., Suk, J.S., Yang, M., Zeitlin, P., Boyle, M.P., Fu, J., Hanes, J.: Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc. Natl. Acad. Sci. U. S. A. 106(46), 19268–19273 (2009). https://doi.org/10.1073/pnas.0905998106
Wang, Y.Y., Lai, S.K., Suk, J.S., Pace, A., Cone, R., Hanes, J.: Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “Slip” through the human mucus barrier. Angew Chem Int Ed Engl. 47(50), 9726–9729 (2008). https://doi.org/10.1002/anie.200803526
Allen, T.M., Cullis, P.R.: Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65(1), 36–48 (2013). https://doi.org/10.1016/j.addr.2012.09.037
Barenholz, Y.: Doxil (R) - The first FDA-approved nano-drug: lessons learned. J. Control. Release. 160(2), 117–134 (2012). https://doi.org/10.1016/j.jconrel.2012.03.020
Szebeni, J., Baranyi, L., Savay, S., Milosevits, J., Bunger, R., Laverman, P., Metselaar, J.M., Storm, G., Chanan-Khan, A., Liebes, L., Muggia, F.M., Cohen, R., Barenholz, Y., Alving, C.R.: Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J. Liposome Res. 12(1–2), 165–172 (2002). https://doi.org/10.1081/LPR-120004790
Adlermoore, J.: Ambisome targeting to fungal-infections. Bone Marrow Transplant. 14, S3–S7 (1994)
Rosenthal, E., Poizot-Martin, I., Saint-Marc, T., Spano, J.P., Cacoub, P., Grp, D.S.: Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. Am. J. Clin. Oncol. 25(1), 57–59 (2002). https://doi.org/10.1097/00000421-200202000-00012
Mayer, A.M.S., Glaser, K.B., Cuevas, C., Jacobs, R.S., Kem, W., Little, R.D., McIntosh, J.M., Newman, D.J., Potts, B.C., Shuster, D.E.: The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol. Sci. 31(6), 255–265 (2010). https://doi.org/10.1016/j.tips.2010.02.005
Gabizon, A., Shmeeda, H., Barenholz, Y.: Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies. Clin. Pharmacokinet. 42(5), 419–436 (2003). https://doi.org/10.2165/00003088-200342050-00002
Grimaldi, N., Andrade, F., Segovia, N., Ferrer-Tasies, L., Sala, S., Veciana, J., Ventosa, N.: Lipid-based nanovesicles for nanomedicine. Chem. Soc. Rev. 45, 6520 (2016)
Boulikas, T.: Clinical overview on Lipoplatin (TM): a successful liposomal formulation of cisplatin. Expert Opin. Investig. Drugs. 18(8), 1197–1218 (2009). https://doi.org/10.1517/13543780903114168
Silverman, J.A., Deitcher, S.R.: Marqibo (R) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother. Pharmacol. 71(3), 555–564 (2013). https://doi.org/10.1007/s00280-012-2042-4
Leonard, R.C.F., Williams, S., Tulpule, A., Levine, A.M., Oliveros, S.: Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet (TM)). Breast. 18(4), 218–224 (2009). https://doi.org/10.1016/j.breast.2009.05.004
Schell, R.F., Sidone, B.J., Caron, W.P., Walsha, M.D., White, T.F., Zamboni, B.A., Ramanathan, R.K., Zamboni, W.C.: Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents. Nanomedicine. 10(1), 109–117 (2014). https://doi.org/10.1016/j.nano.2013.07.005
Wang, A.Z., Langer, R., Farokhzad, O.C.: Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63(63), 185–198 (2012). https://doi.org/10.1146/annurev-med-040210-162544
Maruyama, K.: Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv. Drug Deliv. Rev. 63(3), 161–169 (2011). https://doi.org/10.1016/j.addr.2010.09.003
Torchilin, V.P.: Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4(2), 145–160 (2005). https://doi.org/10.1038/nrd1632
Kirpotin, D., Park, J.W., Hong, K., Zalipsky, S., Li, W.L., Carter, P., Benz, C.C., Papahadjopoulos, D.: Sterically stabilized Anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 36(1), 66–75 (1997). https://doi.org/10.1021/bi962148u
Maruyama, K., Ishida, O., Takizawa, T., Moribe, K.: Possibility of active targeting to tumor tissues with liposomes. Adv. Drug Deliv. Rev. 40(1–2), 89–102 (1999). https://doi.org/10.1016/S0169-409x(99)00042-3
Kumari, A., Yadav, S.K., Yadav, S.C.: Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces. 75(1), 1–18 (2010). https://doi.org/10.1016/j.colsurfb.2009.09.001
Bermudez, H., Brannan, A.K., Hammer, D.A., Bates, F.S., Discher, D.E.: Molecular weight dependence of polymersome membrane structure, elasticity, and stability. Macromolecules. 35(21), 8203–8208 (2002). https://doi.org/10.1021/ma020669l
Discher, D.E., Ahmed, F.: Polymersomes. Annu. Rev. Biomed. Eng. 8, 323–341 (2006). https://doi.org/10.1146/annurev.bioeng.8.061505.095838
Ensign, L.M., Cone, R., Hanes, J.: Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 64(6), 557–570 (2012). https://doi.org/10.1016/j.addr.2011.12.009
Muller, C., Perera, G., Konig, V., Bernkop-Schnurch, A.: Development and in vivo evaluation of papain-functionalized nanoparticles. Eur. J. Pharm. Biopharm. 87(1), 125–131 (2014). https://doi.org/10.1016/j.ejpb.2013.12.012
Tao, Y.Y., Lu, Y.F., Sun, Y.J., Gu, B., Lu, W.Y., Pan, J.: Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability. Int. J. Pharm. 378(1–2), 30–36 (2009). https://doi.org/10.1016/j.ijpharm.2009.05.025
Pauletti, G.M., Gangwar, S., Knipp, G.T., Nerurkar, M.M., Okumu, F.W., Tamura, K., Siahaan, T.J., Borchardt, R.T.: Structural requirements for intestinal absorption of peptide drugs. J. Control. Release. 41(1–2), 3–17 (1996). https://doi.org/10.1016/0168-3659(96)01352-1
Bakhru, S.H., Furtado, S., Morello, A.P., Mathiowitz, E.: Oral delivery of proteins by biodegradable nanoparticles. Adv. Drug Deliv. Rev. 65(6), 811–821 (2013). https://doi.org/10.1016/j.addr.2013.04.006
Lai, S.K., O'Hanlon, D.E., Harrold, S., Man, S.T., Wang, Y.Y., Cone, R., Hanes, J.: Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. U. S. A. 104(5), 1482–1487 (2007). https://doi.org/10.1073/pnas.0608611104
Obach, R.S., Baxter, J.G., Liston, T.E., Silber, B.M., Jones, B.C., MacIntyre, F., Rance, D.J., Wastall, P.: The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 283(1), 46–58 (1997)
Amidon, G.L., Lennernas, H., Shah, V.P., Crison, J.R.: A theoretical basis for a biopharmaceutic drug classification - the correlation of in-Vitro drug product dissolution and in-Vivo bioavailability. Pharm. Res. 12(3), 413–420 (1995). https://doi.org/10.1023/A:1016212804288
Martinez, M.N., G L, A.: A mechanistic approach to understandingthe factors affecting drug absorption:a review of fundamentals. J. Clin. Pharmacol. 42, 620–643 (2002)
des Rieux, A., Ragnarsson, E.G., Gullberg, E., Préat, V., Schneider, Y.-J., Artursson, P.: Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur. J. Pharm. Sci. 25(4), 455–465 (2005)
des Rieux, A., Fievez, V., Théate, I., Mast, J., Préat, V., Schneider, Y.-J.: An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur. J. Pharm. Sci. 30(5), 380–391 (2007)
Antunes, F., Andrade, F., Araújo, F., Ferreira, D., Sarmento, B.: Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs. Eur. J. Pharm. Biopharm. 83(3), 427–435 (2013)
Modi, S., Anderson, B.D.: Determination of drug release kinetics from nanoparticles: overcoming pitfalls of the dynamic dialysis method. Mol. Pharm. 10(8), 3076–3089 (2013). https://doi.org/10.1021/mp400154a
Gupta, P.K., Hung, C.T., Perrier, D.G.: Quantitation of the Release of Doxorubicin from Colloidal Dosage Forms Using Dynamic Dialysis. J. Pharm. Sci. 76(2), 141–145 (1987). https://doi.org/10.1002/jps.2600760211
Leo, E., Cameroni, R., Forni, F.: Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticle conjugates. Int. J. Pharm. 180(1), 23–30 (1999)
Mogollon, C.: In Vitro Release of Curcumin from Polymeric Nanoparticles Using Two-Phase System. University of Illinois at Chicago (2016)
Shah, P., Fritz, J.V., Glaab, E., Desai, M.S., Greenhalgh, K., Frachet, A., Niegowska, M., Estes, M., Jager, C., Seguin-Devaux, C., Zenhausern, F., Wilmes, P.: A microfluidics-based in vitro model of the gastrointestinal human-microbe interface. Nat. Commun. 7, 11535 (2016). https://doi.org/10.1038/ncomms11535
Eisenstein, M.: ARTIFICIAL ORGANS Honey, I shrunk the lungs. Nature. 519(7544), S16–S18 (2015)
Golla, K., Bhaskar, C., Ahmed, F., Kondapi, A.K.: A Target-Specific Oral Formulation of Doxorubicin-Protein Nanoparticles: Efficacy and Safety in Hepatocellular Cancer. J. Cancer. 4(8), 644–652 (2013). https://doi.org/10.7150/jca.7093
Jain, S., Kumar, D., Swarnakar, N.K., Thanki, K.: Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials. 33(28), 6758–6768 (2012). https://doi.org/10.1016/j.biomaterials.2012.05.026
Vong, L.B., Yoshitomi, T., Matsui, H., Nagasaki, Y.: Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer. Biomaterials. 55, 54–63 (2015). https://doi.org/10.1016/j.biomaterials.2015.03.037
Bisht, S., Feldmann, G., Koorstra, J.B.M., Mullendore, M., Alvarez, H., Karikari, C., Rudek, M.A., Lee, C.K., Maitra, A., Maitra, A.: In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol. Cancer Ther. 7(12), 3878–3888 (2008). https://doi.org/10.1158/1535-7163.Mct-08-0476
Qu, D., Wang, L.X., Liu, M., Shen, S.Y., Li, T., Liu, Y.P., Huang, M.M., Liu, C.Y., Chen, Y., Mo, R.: Oral Nanomedicine Based on Multicomponent Microemulsions for Drug-Resistant Breast Cancer Treatment. Biomacromolecules. 18(4), 1268–1280 (2017). https://doi.org/10.1021/acs.biomac.7b00011
Groo, A.C., Bossiere, M., Trichard, L., Legras, P., Benoit, J.P., Lagarce, F.: In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor. Nanomedicine. 10(4), 589–601 (2015). https://doi.org/10.2217/nnm.14.124
Wang, Y.C., Zhang, D.R., Liu, Z.P., Liu, G.P., Duan, C.X., Jia, L.J., Feng, F.F., Zhang, X.Y., Shi, Y.Q., Zhang, Q.: In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery. Nanotechnology. 21(15), 155104 (2010). https://doi.org/10.1088/0957-4484/21/15/155104
Attili-Qadri, S., Karra, N., Nemirovski, A., Schwob, O., Talmon, Y., Nassar, T., Benita, S.: Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc. Natl. Acad. Sci. U. S. A. 110(43), 17498–17503 (2013). https://doi.org/10.1073/pnas.1313839110
Hu, Q.L., Wu, M., Fang, C., Cheng, C.Y., Zhao, M.M., Fang, W.H., Chu, P.K., Ping, Y., Tang, G.P.: Engineering nanoparticle-coated bacteria as oral DNA vaccines for cancer immunotherapy. Nano Lett. 15(4), 2732–2739 (2015). https://doi.org/10.1021/acs.nanolett.5b00570
Claus, B.L., Underwood, D.J.: Discovery informatics: its evolving role in drug discovery. Drug Discov. Today. 7(18), 957–966. doi: Pii S1359-6446(02)02433-9 (2002). https://doi.org/10.1016/S1359-6446(02)02433-9
Kaitin, K.I., DiMasi, J.A.: Pharmaceutical innovation in the 21st Century: new drug approvals in the First Decade, 2000-2009. Clin. Pharmacol. Ther. 89(2), 183–188 (2011). https://doi.org/10.1038/clpt.2010.286
Chaubal, M.V.: Application of formulation technologies in lead candidate selection and optimization. Drug Discov. Today. 9(14), 603–609. doi: Pii S1359-6446(04)03171-X (2004). https://doi.org/10.1016/S1359-6446(04)03171-X
Torchilin, V.P., Lukyanov, A.N.: Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov. Today. 8(6), 259–266. doi: Pii S1359-6446(03)02623-0 (2003). https://doi.org/10.1016/S1359-6446(03)02623-0
Allen, T.M., Cullis, P.R.: Drug delivery systems: Entering the mainstream. Science. 303(5665), 1818–1822 (2004). https://doi.org/10.1126/science.1095833
Sarmento, B., Martins, S., Ferreira, D., Souto, E.B.: Oral insulin delivery by means of solid lipid nanoparticles. Int. J. Nanomedicine. 2(4), 743–749 (2007)
Knop, K., Hoogenboom, R., Fischer, D., Schubert, U.S.: Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 49(36), 6288–6308 (2010). https://doi.org/10.1002/anie.200902672
Acknowledgment
The research of nanoparticle design and production of Ying Liu is supported by NSF CMMI Nanomanufacturing Program (NSF CAREER 1350731).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply
About this chapter
Cite this chapter
Donovan, A.J., Liu, Y. (2019). Oral Nanotherapeutics for Cancer with Innovations in Lipid and Polymeric Nanoformulations. In: Rai, P., Morris, S.A. (eds) Nanotheranostics for Cancer Applications. Bioanalysis, vol 5. Springer, Cham. https://doi.org/10.1007/978-3-030-01775-0_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-01775-0_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-01773-6
Online ISBN: 978-3-030-01775-0
eBook Packages: EngineeringEngineering (R0)